Figure 7: Relative enhancement of the cytotoxic anti-neoplastic potency of gemcitabine-(C4-amide)-[anti-HER2/neu] in dual combination with griseofulvin against chemotherapeutic-resistant mammary adenocarcinoma. Legend: (♦) gemcitabine-(C4-amide)-[anti-HER2/neu] with griseofulvin; (▲) gemcitabine- (C4-amide)-[anti-HER2/neu]; and (■) gemcitabine alone. Chemotherapeuticresistant mammary adenocarcinoma (SKBr-3) monolayer populations were incubated with covalent gemcitabine-(C4-amide)-[anti-HER2/neu] immunochemotherapeutic (+/- grisofulvin 15 μM fixed-concentration) formulated in triplicate at gradient concentrations. Cytotoxic anti-neoplastic potency was measured using a MTT cell vitality assay relative to matched negative reference controls.